Fenretinide and risk reduction of second breast cancer.
Decensi
Andrea
A
E.O. Ospedali Galliera, Division of Medical Oncology, Via Volta 6, Genoa 16128, Italy. andrea.decensi@galliera.it
Zanardi
Silvia
S
Argusti
Alessandra
A
Bonanni
Bernardo
B
Costa
Alberto
A
Veronesi
Umberto
U
D000328:Adult; D000368:Aged; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000517:prevention & control* / Q000601:surgery; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000517:prevention & control* / Q000601:surgery; D005260:Female; D017313:Fenretinide / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000517:prevention & control*; D016896:Treatment Outcome
D016588:Anticarcinogenic Agents; D017313:Fenretinide